Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke

被引:48
作者
Meng, Ran [1 ,6 ]
Li, Zhi-Yong [3 ,4 ]
Ji, Xunming [2 ]
Ding, Yuchuan [2 ]
Meng, Sui [5 ]
Wang, Xiaoying [6 ]
机构
[1] Beijing Univ, Div Neurol, Shijitan Hosp, Clin Med Coll 9, Beijing 100038, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Beijing 100053, Peoples R China
[3] Southeast Univ, Sch Biol Sci & Med Engn, Nanjing, Peoples R China
[4] Univ Cambridge, Cambridge Univ Hosp NHS Fdn Trust, Univ Dept Radiol, Cambridge CB2 0QQ, England
[5] Univ Int Business & Economics, Beijing 100029, Peoples R China
[6] Harvard Univ, Sch Med, Neuroprotect Res Lab, Boston, MA 02129 USA
关键词
Antithrombin III; Fibrinogen; Ischemic stroke; Acute; TISSUE-PLASMINOGEN ACTIVATOR; C-REACTIVE PROTEIN; THERAPY; THROMBOLYSIS; INFARCTION; THROMBOSIS; WINDOW; ATTACK; TIME;
D O I
10.1016/j.clineuro.2010.12.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: The purpose of this study is to examine the feasibility of developing plasma predictive value biomarkers of cerebral ischemic stroke before imaging evidence is acquired. Methods: Blood samples were obtained from 198 patients who attended our neurology department as emergencies - with symptoms of vertigo, numbness, limb weakness, etc. - within 4.5 h of symptom onset, and before imaging evidence was obtained and medical treatment. After the final diagnosis was made by MRI/DWI/MRA or CTA in the following 24-72 h, the above cases were divided into two groups: stroke group and non-stroke group according to the imaging results. The levels of baseline plasma antithrombin III (AT-III), thrombin-antithrombin III (TAT), fibrinogen, D-dimer and high-sensitivity C-reactive protein (hsCRP) in the two groups were assayed. Results: The level of the baseline AT-III in the stroke group was 118.07 +/- 26.22%, which was lower than that of the non-stroke group (283.83 +/- 38.39%). The levels of TAT, fibrinogen, hsCRP were 7.24 +/- 2.28 mu g/L, 5.49 +/- 0.98 g/L, and 2.17 +/- 1.07 mg/L, respectively, which were higher than those of the non-stroke group (2.53 +/- 1.23 mu g/L, 3.35 +/- 0.50 g/L, 1.82 +/- 0.67 mg/L). All the P-values were less than 0.001. The D-dimer level was 322.57 +/- 60.3411 mu g/L, which was slightly higher than that of the non-stroke group (305.76 +/- 49.52 mu g/L), but the P-value was 0.667. The sensitivities of AT-III, TAT, fibrinogen, D-dimer and hsCRP for predicting ischemic stroke tendency were 97.37%, 96.05%, 3.29%, 7.89%, but the specificity was 93.62%, 82.61%, 100% and 100%, respectively, and all the P-values were less than 0.001. High levels of D-dimer and hsCRP were mainly seen in the few cases with severe large-vessel infarction. Conclusions: Clinical manifestations of acute focal neurological deficits were associated with plasma AT-III and fibrinogen. These tests might help the risk assessment of acute cerebral ischemic stroke and/or TIA with infarction tendency in the superacute stage before positive imaging evidence is obtained. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:380 / 386
页数:7
相关论文
共 35 条
[1]  
Al-Buhairi AR, 2002, SAUDI MED J, V23, P13
[2]   Does ABCD2 Score Below 4 Allow More Time to Evaluate Patients With a Transient Ischemic Attack? [J].
Amarenco, Pierre ;
Labreuche, Julien ;
Lavallee, Philippa C. ;
Meseguer, Elena ;
Cabrejo, Lucie ;
Slaoui, Tarik ;
Guidoux, Celine ;
Olivot, Jean-Marc ;
Abboud, Halim ;
Lapergue, Bertrand ;
Klein, Isabelle F. ;
Mazighi, Mikael ;
Touboul, Pierre-Jean .
STROKE, 2009, 40 (09) :3091-3095
[3]   Fibrinogen Independently Predicts the Development of Ischemic Stroke in a Taiwanese Population CVDFACTS Study [J].
Chuang, Shao-Yuan ;
Bai, Chyi-Huey ;
Chen, Wei-Hung ;
Lien, Li-Ming ;
Pan, Wen-Harn .
STROKE, 2009, 40 (05) :1578-1584
[4]   An improved scoring system for identifying patients at high early risk of stroke and functional impairment after an acute transient ischemic attack or minor stroke [J].
Coutts, Shelagh B. ;
Eliasziw, Michael ;
Hill, Michael D. ;
Scott, James N. ;
Subramaniam, Suresh ;
Buchan, Alastair M. ;
Demchuk, Andrew M. .
INTERNATIONAL JOURNAL OF STROKE, 2008, 3 (01) :3-10
[5]  
D'Uva M, 2008, BIOL-TARGETS THER, V2, P897
[6]   Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke [J].
del Zoppo, Gregory J. ;
Levy, David E. ;
Wasiewski, Warren W. ;
Pancioli, Arthur M. ;
Demchuk, Andrew M. ;
Trammel, James ;
Demaerschalk, Bart M. ;
Kaste, Markku ;
Albers, Gregory W. ;
Ringelstein, Eric B. .
STROKE, 2009, 40 (05) :1687-1691
[7]   Development of a metropolitan matrix of primary stroke centers: The Phoenix experience [J].
Demaerschalk, Bart M. ;
Bobrow, Bentley J. ;
Paulsen, Mary .
STROKE, 2008, 39 (04) :1246-1253
[8]   Is Plasma Fibrinogen Useful in Evaluating Ischemic Stroke Patients? Why, How, and When [J].
Di Napoli, Mario ;
Singh, Puneetpal .
STROKE, 2009, 40 (05) :1549-1552
[9]   Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions [J].
dos Santos, Sascha Meyer ;
Klinkhardt, Ute ;
Schneppenheim, Reinhard ;
Harder, Sebastian .
PLATELETS, 2010, 21 (01) :60-66
[10]   The cost of cerebral ischaemia [J].
Flynn, R. W. V. ;
MaWalter, R. S. M. ;
Doney, A. S. F. .
NEUROPHARMACOLOGY, 2008, 55 (03) :250-256